Abstract: An anti-thermosensitization rectification tower comprising a rectification tower, a T-shaped condenser, a baffle plate, a tower bottom, a falling-film reboiler and a recirculation system, wherein the T-shaped condenser is secured exactly on the top of the rectification tower without any pipeline in between, and the circular baffle plate is installed in the T-shaped condenser; an annular sump located between the rectification tower and the T-shaped condenser for collecting the liquid condensed in the T-shaped condenser and channeling it out of the rectification tower into a liquid-collecting tank, and a centrifugal pump utilized to connect together the tower bottom and the falling-film reboiler to form a high-speed circulation system, wherein the tower bottom is an elongated conduit and the falling-film reboiler is in the form of a stout shell-and-tube heat exchanger is provided.

Abstract: A bismuth and magnesium co-doped lithium niobate crystal includes Li2CO3, Nb2O5, Bi2O3 and MgO, wherein the molar ratio of [Li] and [Nb] is 0.90-1.00, the molar percentage of Bi2O3 in the mixture is 0.25-0.80%, and the molar percentage of MgO in the mixture is 3.0-7.0%. The bismuth and magnesium co-doped lithium niobate crystal has enhanced photorefraction, improved photorefractive sensitivity, shortened holographic grating saturation writing time, and the photorefractive diffraction efficiency can reach up to 17%. The response time is only 170 ms, when the holographic storage experiment is carried out using 488 nm continuous laser. Therefore, this crystal can be used in the field of holographic imaging.

Abstract: An optical wavelength detecting device, the device including: a polarizer configured to transform an incident light into a polarized light; a detecting element configured to receive the polarized light and form a temperature difference or a potential difference between two points of the detecting element, wherein the detecting element comprises a carbon nanotube structure including a plurality of carbon nanotubes oriented along the same direction, and angles between a polarizing direction of the polarized light and an oriented direction of the plurality of carbon nanotubes is adjustable; a measuring device electrically connected to the detecting element and configured to measure the temperature difference or the potential difference; a data processor electrically connected to the measuring device and configured to obtain the optical wavelength by calculating and analyzing the temperature difference or the potential difference.

Abstract: The present invention provides applications of a small molecular flavonoid compound in preparing a medication for sensitizing/synergizing tumor radiation therapy as well as reducing radioactive damage. The small molecular flavonoid compound can be naringenin, hesperetin, luteolin and apigenin, etc. The medication contains a small molecular flavonoid compound and a plurality of conventional pharmaceutical additives; wherein the small molecular flavonoid compound is an active ingredient.

Abstract: An optical wavelength detecting device, the device including: a polarizer configured to transform an incident light into a polarized light; a detecting element configured to receive the polarized light and form a temperature difference or a potential difference between two points of the detecting element, wherein the detecting element includes a carbon nanotube structure including a plurality of carbon nanotubes oriented along the same direction, and angles between a polarizing direction of the polarized light and an oriented direction of the plurality of carbon nanotubes is adjustable; a measuring device electrically connected to the detecting element and configured to measure the temperature difference or the potential difference; a data processor electrically connected to the measuring device and configured to obtain the optical wavelength by calculating and analyzing the temperature difference or the potential difference.

Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1 ??(Formula I).

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.

Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.

Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

Abstract: A hard disk drive mounting assembly that includes a disk drive assembly having a base structure that includes a screw hole and a damping insert at least partially surrounding the screw hole. The disk drive assembly further includes a threaded insert positioned in the screw hole of the damping insert.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.

Abstract: A cable-membrane tensegrity structure which is asymmetric, and construction method and design method thereof are provided. The cable-membrane tensegrity structure comprises a central opening and is formed by a ring cable (4) and three layers of radial cables comprising a suspension cable (1), a ridge cable (2) and a valley cable (3), wherein the suspension cable (1) is located above the ridge cable (2), the ridge cable (2) is located above the valley cable (3), wherein one end of each of the suspension cable (1), the ridge cable (2) and the valley cable (3) is connected to the ring cable (4), and the other end of each of the suspension cable (1), the ridge cable (2) and the valley cable (3) is connected to a peripheral supporting structure (7), wherein a coating membrane (5) is tensioned between the ridge cable (2) and the valley cable (3) that are adjacent to each other and function as a skeleton to tension the coating membrane (5).

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

Abstract: A system includes a body having a front end and a back end, a channel within the body that is configured to hold at least a portion of a service unit, a guiderail extending along a portion of the channel and configured to couple with a pushrod, and an adapter configured to couple with a portion of the service unit and a portion of the body. The channel also includes a front opening positioned proximate to the front end of the body, wherein the front opening is configured to allow at least a portion of the service unit, or at least a portion of a connector, to pass through the front opening, and a back opening positioned proximate to the back end of the body, wherein the back opening is configured to allow at least a portion of the pushrod to pass through the back opening.

Abstract: The invention relates to a compound of Formula I: F1—X1-L1-X2—P1—X3-G1??(Formula I).

Abstract: An optical locking system comprises a light emitter, an optical wavelength identifying system, and a locking unit. The optical wavelength identifying system comprises an optical wavelength detecting device, a memory, a modulator, a comparison module, and an instruction module. The optical wavelength detecting device comprises a polarizer, a detecting element, a measuring device, and a data processor. The detecting element configured to form a temperature difference or a potential difference between two points of the detecting element when exposed to the polarized light, wherein the detecting element comprises a carbon nanotube structure comprising a plurality of carbon nanotubes oriented along the same direction, and angles between a polarizing direction of the polarized light and an oriented direction of the plurality of carbon nanotubes is adjustable.

Abstract: A foldable mouse comprises a substrate, a thin-film battery, a touch module, a signal processing module, and a communication module. The substrate is a foldable structure. The thin-film battery is electrically connected to the touch module, the signal processing module, and the communication module; the signal processing module drives the touch module, receives signals from the touch module, and sends the signals to the communication module. The substrate comprises a main body structure sandwiched between a first support plate and a second support plate. The first support plate and the second support plate are symmetrically located at two opposite sides of the main body and foldable connected to the main body structure. The main body structure comprises a first surface and a second surface, and a minidisc is integrated on the second surface.

Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.